{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:45:59Z","timestamp":1792003559926,"version":"4.4.0"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2019,11,12]]},"DOI":"10.1001\/jama.2019.16585","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T12:31:47Z","timestamp":1573561907000},"page":"1780","source":"Crossref","is-referenced-by-count":445,"title":["Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease"],"prefix":"10.1001","volume":"322","author":[{"given":"Anne C.","family":"Goldberg","sequence":"first","affiliation":[{"name":"Washington University School of Medicine, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence A.","family":"Leiter","sequence":"additional","affiliation":[{"name":"Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S. G.","family":"Stroes","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth J.","family":"Baum","sequence":"additional","affiliation":[{"name":"Preventive Cardiology Inc, Boca Raton, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Hanselman","sequence":"additional","affiliation":[{"name":"Esperion Therapeutics Inc, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LeAnne T.","family":"Bloedon","sequence":"additional","affiliation":[{"name":"Esperion Therapeutics Inc, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra D.","family":"Lalwani","sequence":"additional","affiliation":[{"name":"Esperion Therapeutics Inc, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragna M.","family":"Patel","sequence":"additional","affiliation":[{"name":"Esperion Therapeutics Inc, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Esperion Therapeutics Inc, Ann Arbor, Michigan"},{"name":"Currently with Corestat Inc, Ithaca, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Barton","family":"Duell","sequence":"additional","affiliation":[{"name":"Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health & Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"24","key":"joi190117r1","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"joi190117r2","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials.","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"joi190117r3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","article-title":"Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH registry.","volume":"9","author":"deGoma","year":"2016","journal-title":"Circ Cardiovasc Genet"},{"key":"joi190117r4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.atherosclerosis.2016.09.004","article-title":"Low-density lipoprotein cholesterol in a global cohort of 57,885 statin-treated patients.","volume":"255","author":"Gitt","year":"2016","journal-title":"Atherosclerosis"},{"issue":"12","key":"joi190117r5","first-page":"1270","article-title":"Ezetimibe use and LDL-C goal achievement: a retrospective database analysis of patients with clinical atherosclerotic cardiovascular disease or probable heterozygous familial hypercholesterolemia.","volume":"23","author":"Menzin","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"joi190117r6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up.","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"9753","key":"joi190117r7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"joi190117r8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"joi190117r9","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"11","key":"joi190117r10","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","article-title":"Mendelian randomization study of ACLY and cardiovascular disease.","volume":"380","author":"Ference","year":"2019","journal-title":"N Engl J Med"},{"issue":"39","key":"joi190117r11","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias.","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"joi190117r12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"11","key":"joi190117r13","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol.","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"joi190117r14","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance.","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"joi190117r15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"joi190117r16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jacl.2017.04.120","article-title":"Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association.","volume":"11","author":"Cohen","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"17","key":"joi190117r17","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy\u2014European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"joi190117r18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.010376","article-title":"Adherence to statin therapy among US adults between 2007 and 2014.","volume":"8","author":"Colantonio","year":"2019","journal-title":"J Am Heart Assoc"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2754792\/jama_goldberg_2019_oi_190117.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T11:00:51Z","timestamp":1579604451000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2754792"}},"subtitle":["The CLEAR Wisdom Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":18,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2019,11,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2019.16585","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,12]]}}}